Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 7:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 50 matching trials from the live ClinicalTrials.gov search.
Conditions
Healthy, Mental Disorder, Obsessive Compulsive Disorder, Schizophrenia, Tourette Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Tardive Dyskinesia
Interventions
Valbenazine
Drug
Lead sponsor
Yale University
Other
Eligibility
26 Years to 84 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Not applicable Interventional Results available

Effect of Exercise in Parkinsonism

NCT02598973
Conditions
Parkinson's Disease, Drug-induced Parkinsonism
Interventions
Exercise
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 89 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
Interventions
Valbenazine Oral Capsule
Drug
Lead sponsor
Stephen Ruedrich
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Tardive Dyskinesia
Interventions
TDtect
Other
Lead sponsor
iRxReminder
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Brooklyn, New York • Garfield Heights, Ohio
Conditions
Schizophrenia, Schizoaffective Disorder, Tobacco Smoking, Tardive Dyskinesia, Parkinsonism
Interventions
Varenicline
Drug
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Tardive Dyskinesia
Interventions
SD-809, Placebo
Drug
Lead sponsor
Auspex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
44
States / cities
Tuscaloosa, Alabama • Anaheim, California • Glendale, California + 36 more
Completed Early Phase 1 Interventional

Pimavanserin Treatment in TS

NCT04794413
Conditions
Tourette Syndrome, Tardive Dyskinesia
Interventions
Pimavanserin
Drug
Lead sponsor
Joseph Jankovic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions
Valbenazine
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Bryant, Arkansas • Chino, California • Fresno, California + 16 more
Conditions
Tardive Dyskinesia
Interventions
NBI-98854
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
43
States / cities
Anaheim, California • Glendale, California • Irvine, California + 40 more
Conditions
Parkinson Disease, Dyskinesia, Drug-Induced, Levodopa
Interventions
AFQ056
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Sunnyvale, California • Englewood, Colorado • Indianapolis, Indiana
Completed Phase 2Phase 3 Interventional Results available

Aim to Reduce Movements in Tardive Dyskinesia

NCT02195700
Conditions
Tardive Dyskinesia
Interventions
SD-809, Placebo
Drug
Lead sponsor
Auspex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
32
States / cities
Tuscaloosa, Alabama • Anaheim, California • Glendale, California + 29 more
Conditions
Tardive Dyskinesia
Interventions
NBI-98854, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Little Rock, Arkansas • National City, California • San Diego, California + 6 more
Conditions
Akathisia
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 1999
U.S. locations
2
States / cities
Morganton, North Carolina • University Park, Pennsylvania
Conditions
Tardive Dyskinesia
Interventions
levetiracetam, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Tardive Dyskinesia
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Conditions
Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
Interventions
Deutetrabenazine Oral Capsule
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Tardive Dyskinesia
Interventions
NBI-98854, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
21
States / cities
Costa Mesa, California • Fountain Valley, California • Oceanside, California + 17 more
Enrolling by invitation Phase 1 Interventional

Phase 1/2a Study of ANPD001 in Parkinson Disease

NCT06344026
Conditions
Parkinson Disease
Interventions
ANPD001, Custom Device
Biological · Device
Lead sponsor
Aspen Neuroscience
Industry
Eligibility
40 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
9
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 6 more
Conditions
Multiple Sclerosis
Interventions
CI Therapy, CAM treatments
Behavioral
Lead sponsor
National Multiple Sclerosis Society
Other
Eligibility
21 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Conditions
Parkinson Disease, Dyskinesia, Drug-Induced
Interventions
Intravenous Infusion
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Portland, Oregon • Seattle, Washington
Conditions
Tardive Dyskinesia
Interventions
Galantamine
Drug
Lead sponsor
Caroff, Stanley N., M.D.
Individual
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Tardive Dyskinesia
Interventions
Not listed
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
34
States / cities
Little Rock, Arkansas • Anaheim, California • Long Beach, California + 29 more